Part D results
CMS's year-end Part D reconciliation, 2022–2024. When a plan's actual drug costs land well above its bid, CMS shares the loss through risk sharing (the "risk corridors"); when they land well below, the plan pays CMS back. A large positive amount means the plan's drug bid was badly underpriced. 2024 is the latest year CMS has published.
How to read this
Risk sharing: positive = CMS paid the plan (costs ran over the bid by more than the corridor); negative = the plan paid CMS. These are CMS's settled figures. Plans also report risk sharing in their MLR filings, sometimes as an estimate made before CMS settled, so a filing can differ.
Per member per year: risk sharing ÷ Part D member-months × 12. Part D member-months include stand-alone drug plan (PDP) members.
CMS's reconciliation also settles reinsurance (catastrophic drug costs) and low-income cost sharing; those are pass-through subsidies, not a sign of profit or loss, so they're shown on contract pages only.
| 2024 | 2023 | 2022 | 3-year total | Per member per year2024 | Part D members2024 avg | |
|---|---|---|---|---|---|---|
| H8928 Fallon Health | $8.6M | −$659K | $531K | $8.5M | $907 | 9,481 |
| H6596 Fallon Health Weinberg | −$195K | −$75.4K | −$114K | −$384K | −$1,372 | 141 |
| H9001 Fallon Health | $336K | −$895K | −$240K | −$798K | $30 | 11,284 |
| H2219 Fallon Health | −$1.9M | −$685K | −$744K | −$3.4M | −$1,454 | 1,335 |
Red = CMS paid the plan. Sorted by the 3-year total. Parent totals add up each contract under its current parent; CMS also publishes its own parent rollup, which can differ where contracts changed hands.